RxDoctor Payments Data

Patrick Parisi, MD

Cardiovascular Disease · Schenectady, NYNPI 1649286170

Payments from drug & device makers

$4,103in general payments, 2019–2025

Across 126 payments — averaging $32.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$537
  • E.r. Squibb & Sons, L.L.C.$526
  • AstraZeneca$407
  • Actelion Pharmaceuticals US, Inc.$332
  • Pfizer$300
  • Medtronic$279
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$3,80193%
  • Education$3027%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,103 in reported general payments places this provider in the 65th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$241,204
Medicare patients
955
Services billed
3,653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban489$729,950
Repatha SureclickEvolocumab86$85,412
EntrestoSacubitril/Valsartan51$70,993
XareltoRivaroxaban39$52,343
Praluent PenAlirocumab47$26,323
Ezetimibe586$19,306
BrilintaTicagrelor20$17,446
Atorvastatin Calcium1,577$16,810
Metoprolol Succinate1,100$16,408
JardianceEmpagliflozin18$15,813
Potassium Chloride284$8,578
Rosuvastatin Calcium528$6,480
Amlodipine Besylate1,104$5,768
Ranolazine ErRanolazine30$4,164
Losartan Potassium253$2,426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$300$729,950489 claims
NovartisEntresto$537$70,99351 claims
Johnson & JohnsonXarelto$251$52,34339 claims
AstraZenecaBrilinta$407$17,44620 claims
Boehringer IngelheimJardiance$232$15,81318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Schenectady

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →